Bio-Techne Corporation (TECH)

Market Cap	9.28B
Revenue (ttm)	1.20B
Net Income (ttm)	158.10M
Shares Out	158.09M
EPS (ttm)	0.98
PE Ratio	59.94
Forward PE	28.88
Dividend	$0.32 (0.54%)
Ex-Dividend Date	Feb 14, 2025

Volume	1,481,251
Open	59.71
Previous Close	59.95
Day's Range	58.48 - 59.83
52-Week Range	56.60 - 85.57
Beta	1.29
Analysts	Buy
Price Target	81.25 (+38.35%)
Earnings Date	Apr 30, 2025

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In 2024, Bio-Techne's revenue was $1.16 billion, an increase of 1.97% compared to the previous year's $1.14 billion. Earnings were $168.07 million, a decrease of -41.07%.

Analyst Forecast

According to 8 analysts, the average rating for TECH stock is "Buy." The 12-month stock price forecast is $81.25, which is an increase of 38.35% from the latest price.

Price Target

$81.25

(38.35% upside)

Analyst Consensus: Buy